INmune Bio amends license agreements, removes clinical milestones; reports XPro1595 pre-clinical data in TBI-AD model

Inmune Bio, Inc.

Amended INKmune license with Immune Ventures: removed all due diligence including clinical trial and NDA filing requirements.
Amended PITT license: replaced milestones with Phase II first patient dose by June 2026, marketing authorization by June 2031.
Pre-clinical study shows XPro1595 prevents amyloid pathology in mouse model of TBI-induced Alzheimer's disease.
Data presented at AD/PD 2023 conference in Gothenburg, Sweden on April 1, 2023.
XPro1595 neutralizes soluble TNF without affecting transmembrane TNF; currently in clinical trials for neurologic disease.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Inmune Bio, Inc. amended Second PITT Amendment with University of Pittsburgh (effective 2023-04-17).

Action: amendment
Agreement: license
Counterparty: University of Pittsburgh
Effective: 2023-04-17

Exact text from the filing

On April 17, 2023, the Company entered into the Second Amendment to Exclusive License Agreement to the PITT Agreement (the “Second PITT Amendment”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Inmune Bio, Inc. amended INKmune Amendment with Immune Ventures, LLC (effective 2023-04-17).

Action: amendment
Agreement: license
Counterparty: Immune Ventures, LLC
Effective: 2023-04-17

Exact text from the filing

On April 17, 2023, the Company entered into an additional amendment to the INKmune License Agreement (the “INKmune Amendment”) to remove the due diligence requirements of the INKmune License Agreement, including using reasonable commercial efforts to bring licensed products and services to market, removing all initiation of clinical trial requirements, and the filing of an NDA or equivalent upon successful completion of Phase III clinical trials.

View on SEC.gov

Browse all material agreements →

Inmune Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-031332

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.